Successful isavuconazole salvage therapy in a patient with invasive mucormycosis

Infection

Volumn 42, Issue 2, 2014, Pages 429-432

  Ervens, J ^a   Ghannoum, M ^b   Graf, B ^a   Schwartz, S ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Drug monitoring; Isavuconazole; Mucormycosis; Rhizopus oryzae

Indexed keywords

AMLODIPINE; AMOXICILLIN PLUS CLAVULANIC ACID; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; CEFUROXIME; CIPROFLOXACIN; CLINDAMYCIN; CONTRAST MEDIUM; CREATININE; DALTEPARIN; DIPYRONE; ERGOSTEROL; FENTANYL; FLUCLOXACILLIN; HEPARIN; ISAVUCONAZOLE; LOPERAMIDE; LORAZEPAM; LORMETAZEPAM; MESALAZINE; MIRTAZAPINE; MORPHINE; ONDANSETRON; POSACONAZOLE; PREDNISOLONE; PROPOFOL; RANITIDINE; TRAMADOL; VALPROIC ACID; ZYMOSTEROL; ANTIFUNGAL AGENT; NITRILE; PYRIDINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ADULT; AGAR DIFFUSION; ANTIBIOTIC THERAPY; ARTICLE; ARTIFICIAL VENTILATION; BACTERIAL SINUSITIS; BONE DESTRUCTION; CASE REPORT; CHEMOSIS; COMPUTER ASSISTED TOMOGRAPHY; DISEASE DURATION; DRUG ACCUMULATION; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPSILOMETER TEST; FACE; FACE PAIN; FIBULA GRAFT; FOLLOW UP; FUNGUS HYPHAE; GENERAL CONDITION DETERIORATION; HARD PALATE; HEMODIALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERTENSION; IN VITRO STUDY; INTENSIVE CARE; INVASIVE MUCORMYCOSIS; KIDNEY DISEASE; LEUKOCYTE COUNT; MALE; MAXILLA RESECTION; MAXILLA SINUSITIS; MIDDLE AGED; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MUCORMYCOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; ORBIT CELLULITIS; PALATE DISEASE; PARESTHESIA; PHASE 3 CLINICAL TRIAL; PHYSICAL EXAMINATION; PLASTIC SURGERY; PUPIL REFLEX; RASH; RHINOCEREBRAL MUCORMYCOSIS; RHIZOPUS ORYZAE; SALVAGE THERAPY; SOFT TISSUE INFECTION; SWELLING; SYSTEMIC MYCOSIS; TRACHEOSTOMY; TREATMENT DURATION; TRIGEMINAL NERVE; ULCERATIVE COLITIS; BRAIN DISEASES; GENETICS; ISOLATION AND PURIFICATION; MICROBIOLOGY; PHYSIOLOGY; RHIZOPUS; TREATMENT OUTCOME;

ANTIFUNGAL AGENTS; BRAIN DISEASES; HUMANS; MALE; MIDDLE AGED; MUCORMYCOSIS; NITRILES; PYRIDINES; RHIZOPUS; SALVAGE THERAPY; TREATMENT OUTCOME; TRIAZOLES;

EID: 84897500774     PISSN: 03008126     EISSN: 14390973     Source Type: Journal    
DOI: 10.1007/s15010-013-0552-6     Document Type: Article

References (13)

1. Dannaoui E, Schwarz P, Slany M, et al. Molecular detection and identification of zygomycetes species from paraffin-embedded tissues in a murine model of disseminated zygomycosis: a collaborative European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Fungal Infection Study Group (EFISG) evaluation. J Clin Microbiol. 2010;48:2043-6.
2. Ghannoum MA, Rice LB. Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev. 1999;12:501-17. (Pubitemid 29484744)
3. Dojcinovic I, Richter M. Mucormycoses: serious complication of high-dose corticosteroid therapy for traumatic optic neuropathy. Int J Oral Maxillofac Surg. 2008;37:391-4. (Pubitemid 351446097)
4. Walsh TJ, Bloom BE, Kontoyiannis DP. Meeting the challenges of an emerging pathogen: the Henry Schueler 41&9 Foundation International Forum on Mucormycosis. Clin Infect Dis. 2012;54:S1-4.
5. Skiada A, Lanternier F, Groll AH, et al. Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3). Haematologica. 2013;98:492-504.
6. Lanternier F, Dannaoui E, Morizot G, et al. A global analysis of mucormycosis in France: the RetroZygo Study (2005-2007). Clin Infect Dis. 2012;54:S35-43.
7. Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005;41:634-53. (Pubitemid 41170352)
8. Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis. 2008;47:503-9.
9. Skiada A, Pagano L, Groll A, et al. Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. Clin Microbiol Infect. 2011;17:1859-67.
10. Cornely OA, Vehreschild JJ, Ruping MJ. Current experience in treating invasive zygomycosis with posaconazole. Clin Microbiol Infect. 2009;15:S77-81.
11. Nagappan V, Deresinski S. Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent. Clin Infect Dis. 2007;45:1610-7. (Pubitemid 351411847)
12. Verweij PE, Gonzalez GM, Wiederhold NP, et al. In vitro antifungal activity of isavuconazole against 345 mucorales isolates collected at study centers in eight countries. J Chemother. 2009;21:272-81.
13. Schmitt-Hoffmann A, Roos B, Heep M, et al. Single-ascending-dose pharmacokinetics and safety of the novel broad-spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and oral administrations (100, 200, and 400 milligrams) of its prodrug, BAL8557, in healthy volunteers. Antimicrob Agents Chemother. 2006;50:279-85. (Pubitemid 43042933)